TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BerGenBio ASA ( (BRRGF) ) just unveiled an announcement.
Oncoinvent ASA has announced the details of a fully underwritten rights issue to raise NOK 130 million, with a subscription price set at NOK 0.50 per share, representing a 35% discount to the theoretical share price. This move requires a share capital reduction to be approved in an extraordinary general meeting, reflecting the company’s strategic financial adjustments to support its ongoing operations and development programs.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
Oncoinvent is a clinical-stage biotechnology company focused on developing novel radiopharmaceutical therapies against cancer. Their lead product, Radspherin®, targets micro-metastases in the peritoneum post-surgery using radium-224, and is currently undergoing clinical trials in the US and Europe.
Average Trading Volume: 110,225
Current Market Cap: NOK190.2M
Find detailed analytics on BRRGF stock on TipRanks’ Stock Analysis page.